Chapter 45: Antiarrhythmic Agents

The effectiveness of these drugs hinges on the precise manipulation of the cardiac action potential, which consists of five phases: Phase 0 (rapid depolarization via sodium ion influx), Phase 1 (a brief period of equalization), Phase 2 (the plateau stage where calcium enters and potassium exits), Phase 3 (rapid repolarization as potassium flows out), and Phase 4 (the resting state where spontaneous depolarization begins again). Arrhythmias, or dysrhythmias, such as tachycardia (faster-than-normal rate), bradycardia (slower-than-normal rate), premature contractions (PACs or PVCs), and fibrillation (like Atrial Fibrillation or AF), can be triggered by issues including electrolyte disturbances, decreased oxygen delivery (hypoxia), structural damage to conduction pathways, or waste product accumulation. Alterations in heart rhythm severely impact hemodynamics, potentially reducing cardiac output and blood flow to vital organs like the brain and heart muscle. Antiarrhythmic medications are organized into four primary classes based on their mechanism of action: Class I agents (e.g., quinidine, lidocaine, flecainide) function as sodium channel blockers, primarily depressing Phase 0 of the action potential to slow conduction and automaticity. Class II agents (e.g., propranolol) are beta-adrenergic blockers that decrease heart rate and excitability by depressing Phase 4. Class III agents (e.g., amiodarone, sotalol) achieve their effect by blocking potassium channels, which prolongs Phase 3 and the duration of the action potential. Class IV agents (e.g., diltiazem, verapamil) are calcium channel blockers that inhibit calcium movement, thereby delaying Phases 1 and 2, which slows automaticity and conduction, particularly through the atrioventricular (AV) node. Since these drugs alter cardiac electrical activity, a major concern is their potential to be proarrhythmic, meaning they can cause new or more dangerous arrhythmias. Other agents, such as adenosine, are often used for converting supraventricular tachycardias (SVT) due to their rapid, short duration of action, while digoxin is sometimes used for atrial arrhythmias. Due to the high risk of serious adverse effects, nursing considerations require meticulous patient assessment, continuous cardiac monitoring during stabilization, careful dosing adjustments for older adults and those with renal or hepatic impairment, and critical patient education regarding drug interactions, such as the need to avoid antihistamines while taking dofetilide or to avoid foods that alkalinize the urine while taking quinidine.